LUNG CANCER SURGERY MARKET ANALYSIS

The Global Lung Cancer Surgery Market size was valued at US$ 6.06 Bn in 2023 and is expected to reach US$ 8.25 Bn by 2030, grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030.

The lung cancer surgery market has witnessed significant growth and innovation in recent years, driven by advancements in medical technology, increasing awareness about early detection, and improving healthcare infrastructure. Surgical interventions play a crucial role in the management of lung cancer, particularly for patients with localized tumors or those for whom surgery presents a viable option. Procedures like lobectomy, pneumonectomy, and minimally invasive techniques such as video-assisted thoracic surgery (VATS) have gained prominence, offering patients reduced postoperative complications and faster recovery times. This growing demand for effective surgical treatments has spurred investments in research and development, leading to the introduction of novel surgical instruments, robotics, and imaging technologies tailored to enhance the precision and outcomes of lung cancer surgeries.

Geographically, the lung cancer surgery market exhibits variations based on factors such as regional healthcare expenditure, prevalence of lung cancer, and access to advanced medical facilities. Developed economies with robust healthcare systems have witnessed a higher adoption of advanced surgical techniques, contributing to a larger market share. Meanwhile, emerging economies are also witnessing an increased focus on improving lung cancer diagnosis and treatment infrastructure, which is expected to drive market growth in those regions.

Lung Cancer Surgery Market Regional Insights

• North America: North America is the largest market for lung cancer surgery, accounting for a share of over 33.5% in 2023. North America, particularly the U.S and Canada, has well-established healthcare systems and access to advanced surgical techniques. There has been a strong emphasis on minimally invasive surgeries, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries, which lead to faster recovery times and reduced post-operative complications. Research and development efforts in this region have also focused on improving patient outcomes through personalized treatment approaches.
• Europe: Europe is the second-largest market for lung cancer surgery, accounting for a share of over 26.1% in 2023. European countries have been adopting innovative surgical techniques for lung cancer treatment. The emphasis on multidisciplinary care, including surgery, chemotherapy, and radiotherapy, has been prominent. The availability of specialized cancer centers and a well-connected healthcare network has contributed to the adoption of advanced surgical procedures.
• Asia Pacific: Asia Pacific is the fastest-growing market for lung cancer surgery, accounting for a share of over 20.3% in 2023. The Asia Pacific region has seen a rise in lung cancer cases due to factors like increased smoking rates, improving healthcare infrastructure, and increasing awareness about early detection. Countries like China, Japan, and South Korea have been investing in healthcare infrastructure and technology, leading to the growth of lung cancer surgeries. There's a growing trend towards minimally invasive procedures in this region as well.

Figure 1. Global Lung Cancer Surgery Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst View:

The global lung cancer surgery market is expected to witness strong growth over the next decade driven by rising lung cancer incidence rates worldwide. The market will be further boosted by the aging population who are more susceptible to developing lung cancer. Advances in minimally invasive surgical techniques such as video-assisted thoracoscopic surgery (VATS) will provide opportunities for less traumatic and quicker recovery for patients. This is expected to increase acceptance of lung cancer surgery among patients. However, the market still faces challenges from competition from alternative non-surgical treatments such as chemotherapy, immunotherapy and targeted drug therapy. These offer less invasive options but come with their own set of side effects. Product affordability could also restrain the market in price sensitive regions. Furthermore, availability of trained thoracic surgeons remains an issue in many developing countries. North America will likely maintain its dominance in the lung cancer surgery market supported by well-developed healthcare infrastructure and growing healthcare spending. Meanwhile, Asia Pacific is poised to see strongest growth along with Latin America led by rising healthcare investment and growing medical tourism in low and middle-income countries. Physicians will need to carefully evaluate patient’s basis their health condition, tumor stage and size to determine the most effective treatment approach. Surgical techniques employing robotics, 3D systems and intra-operative imaging could vastly improve lung cancer treatment outcomes over the

Lung Cancer Surgery Market Drivers:

• Increasing Prevalence of Lung Cancer: The rising incidence of lung cancer globally has been a major driver of the lung cancer surgery market. As the number of diagnosed cases increases, the demand for surgical interventions, including minimally invasive procedures and traditional open surgeries, also rises. For instance, according to data published on June 26, 2023, by World Health Organization (WHO), the lung cancer is the leading cause of cancer death, with an estimated 1.8 million deaths (18%) in 2020.
• Increasing product launches: Increasing product launches are expected to drive the growth of the market over the forecast period. For instance, in September 2020, Koninklijke Philips N.V., a medical device company, announced the launch of Azurion Lung Edition imaging system for diagnosing and treating lung cancer. Azurion Lung Edition is a 3D-imaging and navigation platform for accelerating lung cancer diagnosis and treatment by combining CT-like 3D images acquired at the tableside with live X-ray guidance and other tools to support image-guided lung procedures.
• Growing Emphasis on Early Detection: Early detection of lung cancer has become a priority for improving patient survival rates. Surgical intervention, often combined with other treatment modalities like chemotherapy and radiation therapy, is a critical component of curative intent for early-stage lung cancer. For instance, according to data published on April 12, 2023, by NBC UNIVERSAL, a new AI tool called Sybil was developed by scientists at the Mass General Cancer Center and the Massachusetts Institute of Technology in Cambridge, U.S. It was shown to accurately predict whether a person will develop lung cancer in the next year 86% to 94% of the time. Sybil is able to detect early signs of lung cancer.
• Increasing adoption of inorganic growth strategies such as partnership: Increasing adoption of inorganic growth strategies such as partnership by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, on August 23, 2023, VOCxi Health, a diagnostics company focused on accurate, non-invasive, mobile disease identification, announced a partnership with Silicon & Software Systems Ltd., a medical device company, to develop and market a lung cancer detection and monitoring device.

Lung Cancer Surgery Market Opportunities:

• Adoption of Minimally Invasive Techniques: The adoption of minimally invasive surgical techniques, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, provides significant opportunities for growth. These approaches offer quicker recovery times, reduced post-operative pain, and shorter hospital stays, making them attractive options for patients and healthcare providers.
• Precision Medicine and Targeted Therapies: Advances in molecular profiling and genetic testing create opportunities for personalized treatment approaches. Identifying specific genetic mutations and biomarkers in lung cancer tumors allows for targeted therapies, which could impact the choice of surgical interventions and lead to better patient outcomes.
• Integration of Imaging Technologies: Continued advancements in imaging technologies like high-resolution computed tomography (CT) scans and positron emission tomography (PET) scans offer opportunities for improved pre-operative planning, precise tumor localization, and accurate staging of lung cancer. These technologies enhance the success of surgical interventions. For instance, on May 17, 2023, Koninklijke Philips N.V. announced the launch of AI-powered CT system to accelerate routine radiology and high-volume screening programs.
• Increasing awareness about lung cancer: Increasing awareness about lung cancer is significantly driving the growth of the global lung cancer surgery market over the forecast period. More and more people are now becoming aware of the causes, risk factors, symptoms, and treatment options of lung cancer. Various non-profit organizations and governmental institutions across the world are consistently running awareness campaigns through different mediums to educate the masses regarding lung cancer prevention and early detection. As a result, more people are getting the required screening tests and routine checkups. Consequently, patients now have the option of undergoing lung resection procedures or tumor excision through early diagnosis of lung cancers. For instance, in August 2022, the National Health Service (NHS) publicly funded healthcare system in England, U.K., launched an awareness campaign Help Us Help You campaign about lung cancer. The campaign targeted the groups of people most at risk including those over 60s, as well as people from more working-class backgrounds who are often more reluctant to visit their GP, which is critical to getting an early diagnosis.

Lung Cancer Surgery Market Trends:

• Technology Advancement: Technology advancement is a major factor that is driving the growth of the global lung cancer surgery market over the forecast period. With rising advancements in surgical techniques and equipment, doctors now have better capabilities to detect and operate on lung cancers. Some of the new technologies that are improving lung cancer surgery outcomes include laser therapy, robotic surgery, intraoperative radiation therapy, stereotactic body radiation therapy etc. For instance, in October 2020, Metro Health, a technology company, announced the launch of robot technology for early diagnosis of lung cancer.
• Research and Development: Increasing research and development activities by key playes is expected to drive the growth of the market over the forecast period. For instance, on August 15, 2023, Assiut University, a governmental university based in Eygpt, initiated a clinical trial titled “The Optimal Sequence of Bronchial Brushing, Forceps Biopsy, and Washing for Diagnosis of Lung Cancer”. The study is estimated to be completed in October 2025.
• Increased Focus on Early Detection: Early detection of lung cancer is gaining importance as it significantly influences patient outcomes. Greater awareness of risk factors, coupled with advancements in diagnostic imaging technologies, contributed to the trend of detecting lung cancer at earlier stages, which is expected to drive the growth of the market over the forecast period.
• Increasing collaboration: Increasing adoption of inorganic growth strategies such as partnership by key players in the market is expected to drive the growth of the market over the forecast period. For instance, in November 2021, GE Healthcare, a diagnostics company, and Optellum Ltd, which develops an imaging biomarker for smart lung cancer detection, announced that they had signed a letter of intent to collaborate to advance precision diagnosis and treatment of lung cancer.

Lung Cancer Surgery Market Restraints:

• High Cost of Lung Cancer Surgery: This high cost puts the surgery out of reach for many patients without proper health insurance. Patients sometimes find themselves unable to pay high co-pay requirements, even for those who have insurance. For instance, according to data published in July 2022 by Dotdash Media, Inc., a digital media company, average lung cancer surgery costs in the U.S. range between US$ 15,000 to over US$ 30,000.
• Post Lung Cancer Surgery Complications: Post lung cancer surgery complications present a significant challenge for the growth of the global lung cancer surgery market. Lung cancer surgery often has the risk of complications owing to the intricate anatomical location and structures of the lungs. For instance, according to data published in August 2021, by BioMed Central Ltd., operates as a science, technology, and medicine publisher, post-lung cancer surgery complications include bronchopleural fistula, pleural empyema, pneumonia, lung atelectasis, haemothorax, chylothorax, etc.
• Lack of awareness in developing regions: Lack of awareness about lung cancer and its treatment options in developing regions is significantly restraining the growth of the global lung cancer surgery market. In many underdeveloped parts of the world, there is very little knowledge about lung cancer and its symptoms amongst the general population as well as healthcare workers. This is largely due to the lack of patient education programs and resources to spread information about such a critical disease. People in rural and remote areas remain highly uninformed about the early signs and risk factors of lung cancer. As a result, most cases go undiagnosed until it reaches advanced stages, reducing the chances of effective surgery.

Counterbalances: As a result, the key market players need to focus on spreading awareness about lung cancer and its surgeries and treatment options.

Figure 2. Global Lung Cancer Surgery Market Share (%), By Product Type, 2023

To learn more about this report, request a free sample copy

Recent Developments

New product launches

• In May 2022, Olympus Corporation, manufacturer of optical and digital precision technology, launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope. The BF-UC190F is a new generation of EBUS bronchoscope that offers improved image quality and navigation capabilities. It is designed to help surgeons better visualize and biopsy lung cancer lesions.
• In February 2022, Intuitive Surgical Inc., a company which develops, manufactures, and markets products that enable physicians and healthcare providers, acquired Orpheus Medical. Orpheus Medical is a developer of robotically-assisted lung biopsy systems. The acquisition of Orpheus Medical will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In December 2020, Medtronic, a medical device company, announced the launch of Tri-Staple EEA Circular Stapler in India. The new Tri-Staple Technology comprises a sloped cartridge face that delivers less stress on tissue. It also offers consistent performance over a broad range of tissue thicknesses and allows for greater perfusion into the staple line. 

Acquisition and partnerships

• In February 2023, Intuitive Surgical Inc., a company which develops, manufactures, and markets products that enable physicians and healthcare providers, acquired Auris Health Inc., a medical device company, Auris Health is a developer of robotically-assisted bronchoscopy systems. The acquisition of Auris Health will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In December 2022, Clinithink, a technology company, announced partnership with AstraZeneca, a biopharmaceutical company, to detect early stage lung cancer
• In March 2021, Agilent Technologies Inc., a provider of instruments, reagents, software, services, and consumables, announced it had entered into a definitive agreement to acquire Resolution Bioscience Inc., a company focused on the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent Technologies Inc’s., capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.

Top companies in Lung Cancer Surgery Market

• Ethicon (Johnson & Johnson)
• Medtronic
• Intuitive Surgical
• Olympus Corporation
• Karl Storz
• Accuray Incorporated
• AngioDynamics
• Varian Medical Systems
• Siemens Healthineers
• Atricure, Inc.
• Novadaq Technologies Inc.
• GE Healthcare
• Scanlan International Inc

Definition: Lung cancer surgery is an option for some patients depending on the type, location and stage of their lung cancer and other medical conditions. Attempts to cure lung cancer with the surgery involve removing the tumor along with some surrounding lung tissue and often lymph nodes in the region of the tumor. Lung cancer surgery involves the surgical removal of malignant tumors or affected lung tissue to treat lung cancer. It can encompass various techniques, including open surgery and minimally invasive procedures like video-assisted thoracoscopic surgery (VATS) or robotic-assisted surgery.